⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BMY News
Bristol-Myers Squibb Co.
U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS ® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*
businesswire.com
BMY
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight
globenewswire.com
CYTK
NVO
BCDA
AZN
MESO
GEHC
BSX
MDT
ABT
LIVN
OSCR
EL
BMY
ARE
AVT
RNTX
IPO Education Foundation Names Medtronic's Dr. William J. Peine as 2026 Inventor of the Year
prnewswire.com
MDT
BMY
Drug Repurposing Market - Global Strategic Business Report: Forecasts Growth to $37.3Billion by 2030, Profiling AbbVie, AstraZeneca, Pfizer, Novartis & Johnson & Johnson
globenewswire.com
ABBV
AZN
PFE
NVS
JNJ
AMGN
BMY
GILD
BIIB
TXMD
UTHR
Esophageal Cancer - 7MM Market Insights, Epidemiology, Competitive Landscape, and Forecast - 2036 | 6.0% CAGR Fueled by Immunotherapy and Precision Oncology
globenewswire.com
MRK
BMY
AZN
ABBV
AMGN
JAZZ
ZYME
BIIB
Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) - Market Insights, Epidemiology, and Forecast - 2036 | Radioligand Innovation Unlocks 7MM Growth Opportunities
globenewswire.com
EXEL
BMY
PFE
REGN
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
globenewswire.com
MRK
BMY
JNJ
PDS
BNTX
INO
IMPP
CUE
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
globenewswire.com
BMY
GILD
JNJ
Synthetic Biology Market Size, Share, Growth, Trends, Applications, Competitive Landscape, and Forecast, 2026 to 2034 | 17.6% CAGR Fuels AI-Driven Biomanufacturing Opportunities
globenewswire.com
GNS
TWST
TMO
BMY
GEN
CODX
MRK
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
globenewswire.com
AZN
GILD
MRK
PFE
BMY
JNJ
TEVA